Review of the Life Saving Drugs Program (LSDP)
Page last updated: 28 January 2018
Subscribe to news updates for the latest information regarding reviews, including public consultation, and publication of reviews
Release of the Life Saving Drugs Program Review Report
The Minister is pleased to announce the release of the LSDP Review report and the Government response to the Review.
- Report to the Australian Government (PDF 514KB) - (Word 658KB) and Consultation Report (PDF 1.5MB) - (Word 419KB)
- Government Response to the Review of the LSDP (PDF 478KB) - (Word 88KB)
The Minister’s press release is available on the Minister’s web page.
On 9 April 2014, the Minister for Health, the Hon Peter Dutton MP, announced that the Post-market Review of the Life Saving Drugs Program (LSDP Review) would proceed.
The LSDP Review is an opportunity to review the current program in order to ensure that Australians with very rare conditions continue to have subsidised access to much-needed, expensive medicines.
The Review examines important issues such as access and equity, value for money and the future administration of the program.
During the LSDP Review, patients currently treated through this program will continue to receive subsidised access to treatment, new patients can continue to apply for access to treatment and applications for new medicines seeking LSDP listing will continue to be considered.
Terms of Reference
- Review the clinical effectiveness and safety of medicines currently subsidised through the LSDP.
- Review emerging clinical treatments and diseases, including those that identify sub-groups by molecular target, which could potentially seek subsidisation through the LSDP in the future.
- Conduct an international comparison of subsidisation of drugs for rare diseases and the definitions for a rare/ultra-rare disease.
- Compare the subsidisation and equity principles of the Pharmaceutical Benefits Scheme and the LSDP.
- Assess the value for money of the medicines subsidised on the LSDP by evaluating the benefit of each drug’s treatment outcomes, including in terms of quality of life achieved through the program, and their cost.
- Review the administration of the LSDP, including the Guidelines with which the program is administered for each condition, and assess alternative administration systems.
- Establish a framework for data collection on rare diseases in Australia and assess how this could function internationally.
Reference Group Membership
Professor Andrew Wilson (Chair)
Professor David Sillence – Clinical Expert
Professor David Isaacs – Clinical Expert
Professor Anne Tonkin – Clinical Expert
Professor Jane Hall – Health Economist
Professor Paul Komesaroff – Medical Ethicist
Mrs Lesley Murphy – Consumer Representative
Ms Ainslie Cahill – Consumer Representative
Public Submissions addressing the Terms of Reference
The public submission process closed at 5pm Monday, 10 November 2014.
Submissions received by the Department are available on the Public consultation page.
Public consultation on the LSDP Issues paper may be in lieu of a stakeholder forum.
Public Submissions addressing the Issues Paper
The submissions process closed 5pm Monday 18 May 2015.
Submissions received by the Department will be made public on the Public consultation page unless requested otherwise.
LSDP Review: Technical Assessment Report
The Department commissioned the University of Adelaide to develop a Report addressing Terms of Reference 1, 2, 3, 5 and 7 of the Review on drugs currently included on the LSDP to inform the LSDP reference group. The Report is available below.
Further information regarding the LSDP is available from the Department of Health website.